Company: DAWN
Filing Date: 2025-11-13
Form Type: SC TO-C
Source: 0001104659-25-110815
Chunk: 14

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-13
Form: SC TO-C
Chunk 14
---
00 per share |

| · | First commercial sale of Emi-Le in a major EMA market: $2.00 per share |

| · | First commercial sale of Emi-Le in Japan: $1.00 per share |

| · | Annual net sales of Emi-Le exceed $100 million by 2032: $2.00 per share |

| · | Annual net sales of Emi-Le exceed $200 million by 2035: $4.00 per share |

| · | Annual net sales of Emi-Le exceed $300 million by 2037: $6.00 per share |

Day One expects to finance the acquisition with existing cash resources.
Day One’s strong cash position and financial profile is expected to enable development of Emi-Le through potential approval with
no additional financing required.

The transaction is expected to close by the end of January 2026,
subject to receipt of applicable regulatory approvals and the satisfaction of other customary conditions.

Advisors

Gordon Dyal & Co., LLC is acting as the exclusive financial
advisor to Day One, with Fenwick & West LLP serving as legal counsel. TD Cowen is acting as financial advisor to Mersana, with
Wilmer Cutler Pickering Hale and Dorr LLP serving as legal counsel.

Conference Call

Day One will host a conference call and webcast today, Nov. 13 at 8:00 am Eastern Time. To access the live conference call by phone, dial 877-704-4453 (domestic) or 201-389-0920 (international), and provide the access code 13757215. Live audio webcast will be accessible from the page.
To ensure a timely connection to the webcast, it is recommended that participants register at least 15 minutes prior to the scheduled
start time. An archived version of the webcast will be available for replay on the Events section of the page for 30 days following the event.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a commercial-stage
biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical
unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have
with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development
and redefine what’s possible for all people living with cancer—reg